DrugPatentWatch Database Preview

Details for Patent: 6,790,459

« Back to Dashboard

Which drugs does patent 6,790,459 protect, and when does it expire?

Patent 6,790,459 protects ACTOPLUS MET XR and FORTAMET and is included in two NDAs.

This patent has fifteen patent family members in nine countries.

Summary for Patent: 6,790,459

Title:	Methods for treating diabetes via administration of controlled release metformin
Abstract:	A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (T.sub.max) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.
Inventor(s):	Cheng; Xiu Xiu (Davie, FL), Chen; Chih-Ming (Davie, FL), Jan; Steve (Coral Springs, FL), Chou; Joseph (Manassas, VA)
Assignee:	Andrx Labs, LLC (Davie, FL)
Application Number:	09/705,625
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,790,459
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 6,790,459

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-001	May 12, 2009		DISCN	Yes	No						ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
Takeda Pharms Usa	ACTOPLUS MET XR	metformin hydrochloride; pioglitazone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022024-002	May 12, 2009		DISCN	Yes	No						ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
Andrx Labs Llc	FORTAMET	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021574-002	Apr 27, 2004		DISCN	Yes	No						METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
Andrx Labs Llc	FORTAMET	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021574-001	Apr 27, 2004		DISCN	Yes	No						METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION

International Family Members for US Patent 6,790,459

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005239716
Australia	3083002
Brazil	0115390
Canada	2427195
Canada	2564750
European Patent Office	1335708
European Patent Office	1723948